Navidea Biopharmaceuticals Adds New Member to Board of Directors

  Navidea Biopharmaceuticals Adds New Member to Board of Directors

Business Wire

DUBLIN, Ohio -- November 15, 2013

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company
focused on precision diagnostic radiopharmaceuticals, today announced that
Michael M. Goldberg, MD, MBA has been appointed to the Navidea Board of

Michael M. Goldberg has been a Managing Partner of Montaur Capital Partners
since January 2007. Dr. Goldberg served as the Chief Executive Officer of
Emisphere Technologies, Inc., from August 1990 to January 2007, Chairman of
the Board of Directors from November 1991 to January 16, 2007 and President
from August 1990 to October 1995. Prior to that, he served as Vice President
of The First Boston Corp., where he was a founding member of the Healthcare
Banking Group. He is or has been a Director of Alliqua, Inc., CorNova, Inc.,
Urigen Pharmaceuticals, Inc. and Adventrx Pharmaceuticals Inc. Dr. Goldberg
received a B.S. from Rensselaer Polytechnic Institute, an MD from Albany
Medical College of Union University in 1982 and an MBA from Columbia
University Graduate School of Business in 1985.

“We are pleased to have Michael join the Board,” said Gordon Troup, Chairman
of the Navidea Board of Directors. “Michael brings a wealth of knowledge of
the financial and biopharmaceutical industries that make him an extremely
valuable resource to our Board as we continue to execute on our growth plans.”

“I am excited to be joining the Board and have the opportunity to help deliver
the greatest possible impact to patients and the medical community and return
for investors with Navidea’s industry leading precision diagnostic products
and technologies,” said Dr. Goldberg. “I look forward to working with the
Board and Management to help Navidea realize the potential I believe
Lymphoseek®, the Company’s pipeline, and Navidea’s business model have.”

About Navidea Biopharmaceuticals, Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical
company focused on the development and commercialization of precision
diagnostics and radiopharmaceutical agents. Navidea is developing multiple
precision diagnostic products and platforms including NAV4694, NAV5001,
Manocept™ and RIGScan™,to help identify the sites and pathways of undetected
disease and enable better diagnostic accuracy, clinical decision-making and,
ultimately, patient care. Lymphoseek^® (technetium 99m tilmanocept) Injection,
^ Navidea’s first commercial product from the Manocept platform, was approved
by the FDA in March 2013. Navidea’s strategy is to deliver superior growth and
shareholder return by bringing to market novel radiopharmaceutical agents and
advancing the Company’s pipeline through selective acquisitions, global
partnering and commercialization efforts. For more information, please visit

The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe
harbor for forward-looking statements made by or on behalf of the Company.
Statements in this news release, which relate to other than strictly
historical facts, such as statements about the Company’s plans and strategies,
expectations for future financial performance, new and existing products and
technologies, anticipated clinical and regulatory pathways, and markets for
the Company’s products are forward-looking statements within the meaning of
the Act. The words “believe,” “expect,” “anticipate,” “estimate,” “project,”
and similar expressions identify forward-looking statements that speak only as
of the date hereof. Investors are cautioned that such statements involve risks
and uncertainties that could cause actual results to differ materially from
historical or anticipated results due to many factors including, but not
limited to, the Company’s continuing operating losses, uncertainty of market
acceptance of its products, reliance on third party manufacturers, accumulated
deficit, future capital needs, uncertainty of capital funding, dependence on
limited product line and distribution channels, competition, limited marketing
and manufacturing experience, risks of development of new products, regulatory
risks and other risks detailed in the Company’s most recent Annual Report on
Form 10-K and other Securities and Exchange Commission filings. The Company
undertakes no obligation to publicly update or revise any forward-looking


Navidea Biopharmaceuticals
Brent Larson, 614-822-2330
Executive VP & CFO
Sharon Correia, 978-655-2686
Associate Director, Corporate Communications
Press spacebar to pause and continue. Press esc to stop.